Primary Antiphospholipid Antibody Syndrome and Retinal Occlusive Vasculopathy

Central retinal vein and ophthalmic artery occlusion in primary antiphospholipid syndrome

“…[2][3][4][5] Iris neovascularization tends to occur early, 6 as was demonstrated in our patient. Castanon et al 3 reported a high prevalence of ocular disease in patients with primary antiphospholipid syndrome, with 88% of patients (15 out of 17 patients) demonstrating funduscopic abnormalities, and 29% of patients having vaso-occlusive retinopathy.…”

“…The frequency of ocular vasoocclusive disorders in patients with this syndrome ranges from 0.5 to 8%, with the majority affecting the retinal vasculature. [2][3][4][5] Both the arterial and venous systems may be involved.…”

“…[2][3][4][5][6] We report a case of a 60-year-old woman with primary antiphospholipid syndrome, who developed consecutive occlusion of the central retinal vein and ophthalmic artery. This is the first reported case in patients with this syndrome.…”

Branch Retinal Artery Occlusion as a Presenting Feature of Apla Syndrome and Homocysteinemia

“…Classically, APS has been associated with unilateral and bilateral central retinal vein occlusion (CRVO), central retinal artery occlusion (CRAO), branched retinal vein occlusion (BRVO) and branched retinal artery occlusion (BRAO). 11,12 There is great disparity in the literature with regard to the prevalence of APS associated vaso-occlusive retinopathy, ranging from 8 to 29%. 13 Diagnosis of antiphospholipid antibody syndrome is made by revised SAPPORO'S criteria.…”

Determinación de factores trombofílicos en pacientes con trombosis venosas retinianas

“…Ambos casos se presentan con mayor frecuencia cuando se asocian al síndrome antifosfolípido (SAF), especialmente cuando en éste hay presencia de anticuerpos anticardiolipinas y, en menor proporción, cuando hay anticoagulante lúpico [10][11][12] . El SAF es parte de una condición clínica llamada trombofilia, que puede definirse, en general, como una predisposición, hereditaria o adquirida, para la aparición de trombosis venosa recurrente que, en ocasiones, se presenta en sitios inusuales del organismo [13][14][15][16] .…”